Menu Search
Equities

Shanghai Fosun Pharmaceutical Group Co Ltd

2196:HKG

Shanghai Fosun Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)14.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.09m
  • 1 Year change-24.16%
  • Beta0.7372
Data delayed at least 15 minutes, as of Nov 26 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform3
Hold3
Sell0
Strong Sell0

Share price forecast in CNY

The 6 analysts offering 12 month price targets for Shanghai Fosun Pharmaceutical (Group) have a median target of 16.31, with a high estimate of 20.02 and a low estimate of 13.01. The median estimate represents a 16.48% increase from the last price of 14.00.
High43.0%20.02
Med16.5%16.31
Low-7.1%13.01

Dividends

In 2023, Shanghai Fosun Pharmaceutical Group Co Ltd reported a dividend of 0.27 CNY, which represents a 32.88% decrease from last year. The 5 analysts covering the company expect dividends of 0.32 CNY for the upcoming fiscal year, an increase of 16.25%.
Div growth (TTM)-32.88%
More ▼

Earnings history & estimates in CNY

On Oct 29, 2024, Shanghai Fosun Pharmaceutical (Group) reported 3rd quarter 2024 earnings of 0.29 per share. This result was in line with the consensus of the 2 analysts following the company and exceeded last year's 3rd quarter results by 61.11%.
The next earnings announcement is expected on Mar 31, 2025.
Average growth rate+78.47%
Shanghai Fosun Pharmaceutical (Group) reported annual 2023 earnings of 0.90 per share on Mar 26, 2024.
Average growth rate-5.10%
More ▼

Revenue history & estimates in CNY

Shanghai Fosun Pharmaceutical (Group) had 3rd quarter 2024 revenues of 10.53bn. This bettered the 10.34bn estimate of the one analyst covering the company. The same period last year the company did not report revenues.
Average growth rate+1.47%
Shanghai Fosun Pharmaceutical (Group) had revenues for the full year 2023 of 41.25bn. This was 5.85% below the prior year's results.
Average growth rate+10.49%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.